EN
中文
EN
Who We Are
Newsroom
Innovation
Products
Investor Relations
Careers
Contact Us
Information Disclosure
Home
>
Investor Relations
>
Information Disclosure
H Share
INSIDE INFORMATION RESULTS FORECAST FOR THE YEAR 2023
VOLUNTARY ANNOUNCEMENT OBTAINING THE FINAL REPORT OF PHASE III CLINICAL TRIAL OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (CRM197, TT VECTOR)
2024 FIRST EGM CIRCULAR
Form of Proxy for use at the 2024 First Extraordinary General Meeting to be held on Wednesday, February 21, 2024
NOTICE OF THE 2024 FIRST EXTRAORDINARY GENERAL MEETING
TERMS OF REFERENCE FOR THE REMUNERATION AND ASSESSMENT COMMITTEE OF THE BOARD
TERMS OF REFERENCE FOR THE NOMINATION COMMITTEE OF THE BOARD
TERMS OF REFERENCE OF THE AUDIT COMMITTEE OF THE BOARD
PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND RULES OF PROCEDURES
VOLUNTARY ANNOUNCEMENT INITIATION OF PHASE I CLINICAL TRIAL AND COMPLETION OF FIRST PATIENT ENROLLMENT FOR RECOMBINANT POLIOMYELITIS VACCINE
1
11
12
13
14
15
52
津公网安备12011602300399
